BACKGROUND: People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions to address opioid use disorder and drug use-related harms. The impact of concurrent initiation of opioid agonist therapy (OAT) on HCV treatment and drug use outcomes is unknown. METHODS: In this prospective, open-label, observational trial at a harm reduction organization's drop-in center in Washington, DC, 100 patients with chronic HCV infection, opioid use disorder, and ongoing injection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenorphine initiation. The primary end point was sustained virologic response (SVR), and secondary end points included uptake of and retention in OAT, change in risk behavior, and determinants of SVR. RESULTS: Eighty-two patients (82%) achieved SVR, which was not associated with baseline OAT status (P = .33), on-treatment drug use (P >.99), or imperfect daily adherence (P = .35) but was significantly associated with completing 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at week 24 (P = .01). Of 67 patients not already receiving OAT at baseline, 53 (79%) started OAT. At week 24, 68 (68%) patients were receiving OAT. Receipt of OAT was associated with fewer opiate-positive urine drug screens (P = .003), lower human immunodeficiency virus risk-taking behavior scores (P < .001), and lower rates of opioid overdose (P = .04). CONCLUSIONS: The Novel Model of Hepatitis C Treatment as an Anchor to Prevent HIV, Initiate Opioid Agonist Therapy, and Reduce Risky Behavior study demonstrates high uptake of buprenorphine collocated with HCV treatment, and it shows that concurrent initiation of OAT with HCV treatment can result in high rates of SVR while reducing risks associated with drug use. CLINICAL TRIALS REGISTRATION: NCT03221309.
BACKGROUND:People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions to address opioid use disorder and drug use-related harms. The impact of concurrent initiation of opioid agonist therapy (OAT) on HCV treatment and drug use outcomes is unknown. METHODS: In this prospective, open-label, observational trial at a harm reduction organization's drop-in center in Washington, DC, 100 patients with chronic HCV infection, opioid use disorder, and ongoing injection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenorphine initiation. The primary end point was sustained virologic response (SVR), and secondary end points included uptake of and retention in OAT, change in risk behavior, and determinants of SVR. RESULTS: Eighty-two patients (82%) achieved SVR, which was not associated with baseline OAT status (P = .33), on-treatment drug use (P >.99), or imperfect daily adherence (P = .35) but was significantly associated with completing 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at week 24 (P = .01). Of 67 patients not already receiving OAT at baseline, 53 (79%) started OAT. At week 24, 68 (68%) patients were receiving OAT. Receipt of OAT was associated with fewer opiate-positive urine drug screens (P = .003), lower human immunodeficiency virus risk-taking behavior scores (P < .001), and lower rates of opioid overdose (P = .04). CONCLUSIONS: The Novel Model of Hepatitis C Treatment as an Anchor to Prevent HIV, Initiate Opioid Agonist Therapy, and Reduce Risky Behavior study demonstrates high uptake of buprenorphine collocated with HCV treatment, and it shows that concurrent initiation of OAT with HCV treatment can result in high rates of SVR while reducing risks associated with drug use. CLINICAL TRIALS REGISTRATION: NCT03221309.
Authors: Jason Grebely; Olav Dalgard; Brian Conway; Evan B Cunningham; Philip Bruggmann; Behzad Hajarizadeh; Janaki Amin; Julie Bruneau; Margaret Hellard; Alain H Litwin; Philippa Marks; Sophie Quiene; Sharmila Siriragavan; Tanya L Applegate; Tracy Swan; Jude Byrne; Melanie Lacalamita; Adrian Dunlop; Gail V Matthews; Jeff Powis; David Shaw; Maria Christine Thurnheer; Martin Weltman; Ian Kronborg; Curtis Cooper; Jordan J Feld; Chris Fraser; John F Dillon; Phillip Read; Ed Gane; Gregory J Dore Journal: Lancet Gastroenterol Hepatol Date: 2018-01-06
Authors: Gregory J Dore; Frederick Altice; Alain H Litwin; Olav Dalgard; Edward J Gane; Oren Shibolet; Anne Luetkemeyer; Ronald Nahass; Cheng-Yuan Peng; Brian Conway; Jason Grebely; Anita Y M Howe; Isaias N Gendrano; Erluo Chen; Hsueh-Cheng Huang; Frank J Dutko; David C Nickle; Bach-Yen Nguyen; Janice Wahl; Eliav Barr; Michael N Robertson; Heather L Platt Journal: Ann Intern Med Date: 2016-08-09 Impact factor: 25.391
Authors: Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem Journal: N Engl J Med Date: 2015-11-16 Impact factor: 91.245
Authors: Leah Harvey; Jessica L Taylor; Sabrina A Assoumou; Jessica Kehoe; Elissa M Schechter-Perkins; Edward Bernstein; Alexander Y Walley Journal: J Addict Med Date: 2021 Nov-Dec 01 Impact factor: 3.702
Authors: Noor Taweh; Esther Schlossberg; Cynthia Frank; Ank Nijhawan; Irene Kuo; Kevin Knight; Sandra A Springer Journal: Int J Drug Policy Date: 2021-05-18
Authors: Alysse G Wurcel; Jessica Reyes; Julia Zubiago; Peter J Koutoujian; Deirdre Burke; Tamsin A Knox; Thomas Concannon; Stephenie C Lemon; John B Wong; Karen M Freund; Curt G Beckwith; Amy M LeClair Journal: PLoS One Date: 2021-05-26 Impact factor: 3.240
Authors: Amanda Rosecrans; Robert Harris; Ronald E Saxton; Margaret Cotterell; Meredith Zoltick; Catherine Willman; Ingrid Blackwell; Joy Bell; Darryl Hayes; Brian Weir; Susan Sherman; Gregory M Lucas; Adena Greenbaum; Kathleen R Page Journal: J Subst Abuse Treat Date: 2021-06-24
Authors: Kristi Hill; Laura Nussdorf; Julia D Mount; Rachel Silk; Chloe Gross; David Sternberg; Phyllis Bijole; Miriam Jones; Randy Kier; Dana Mccullough; Poonam Mathur; Shyam Kottilil; Henry Masur; Sarah Kattakuzhy; Elana S Rosenthal Journal: J Addict Med Date: 2022 Jan-Feb 01 Impact factor: 3.702